Astragaloside IV prevents calpain-1-mediated cardiac hypertrophy and fibrosis induced by diabetes
Astragalosid IV verhindert durch Diabetes induzierte kardiale Hypertrophie und Fibrose über Calpain-1
Frontiers in Cardiovascular Medicine · 05.02.2026 · 13
DOI: 10.3389/fcvm.2026.1670472 ↗Auf einen Blick
In Maus- und Zellmodellen für diabetische Kardiomyopathie verbesserte Astragalosid IV die systolische und diastolische Funktion sowie Hypertrophie und Fibrose. Der Effekt war mit Calpain-1-Knockout ähnlich.
Fragestellung
Ob Astragalosid IV seine Schutzwirkung bei diabetischer Kardiomyopathie über Calpain-1 vermittelt.
Methode
In-vivo- und In-vitro-Studie mit Capn1 EK684−/−-Mäusen, H9c2-Zellen und kardialen Fibroblasten unter Hochglukose; Intervention mit unterschiedlichen Dosen Astragalosid IV.
Ergebnisse
Astragalosid IV normalisierte den Blutzucker bei Mäusen nicht vollständig, verbesserte aber Herzfunktion, Hypertrophie und Fibrose. Calpain-1-Überexpression hob den Schutz vor Hochglukose-Schädigung auf.
Schlussfolgerung der Autor:innen
Astragalosid IV kann intrazelluläre Ca2+-Überladung, Apoptose und oxidativen Stress über die Regulation des Calpain-1/CaMKII-Signalwegs verringern und dadurch diabetisch bedingte Hypertrophie und Fibrose verbessern.
Kernaussagen
- Herzfunktion, Hypertrophie und Fibrose besserten sich unter Astragalosid IV
- Calpain-1-Knockout wirkte ähnlich wie Astragalosid IV
- Calpain-1-Überexpression machte den Schutz durch Astragalosid IV zunichte
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 05.02.2026. Verfasst von Qinglong Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Second Hospital of Tianjin Medical University…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Astragaloside IV (AsIV) has been reported to alleviate diabetes-induced endothelial dysfunction by inhibiting calpain-1. This study aimed to determine whether the same mechanism underlies its protective effect against diabetic cardiomyopathy (DCM).
Methods
At the in vivo level, calpain-1 knockout mice with the genotype Capn1 EK684−/− (Capn1 EK684 knockout mice) were used to establish a type 2 diabetic cardiomyopathy model. At the in vitro level, H9c2 cells and cardiac fibroblasts were stimulated with high glucose to construct corresponding models. Meanwhile, a calpain-1 overexpression lentivirus was constructed to assess the effect of calpain-1 on myocardial cell injury. Different doses of AsIV were then used to intervene in diabetic mice and H9c2 cells. Body weight, blood glucose, myocardial hypertrophy, myocardial fibrosis, cardiac function, Ca 2+ overload and its regulation, myocardial cell apoptosis and oxidative stress were evaluated in the current study.
Results
AsIV could not completely normalize blood glucose in mice, but could significantly improve cardiac systolic and diastolic function, myocardial hypertrophy and fibrosis. The beneficial effect of calpain-1 gene knockout on diabetic cardiomyopathy was similar to that of AsIV, and calpain-1 knockout did not further enhance the beneficial effect of AsIV. Calpain-1 overexpression abolished the beneficial effect of AsIV on high glucose induced H9c2 cell injury and fibroblast proliferation. In addition, the intracellular Ca 2+ overload, abnormal levels of sarco/endoplasmic reticulum Ca 2+ -ATPase 2a (SERCA2a), phosphorylation of phospholamban (p-PLN) and ryanodine receptor 2 (p-RyR2), apoptosis and oxidative stress associated with DCM were also improved by AsIV or calpain-1 knockout, and AsIV has the capacity to suppress the overactivation of calpain-1 and calcium/calmodulin-dependent protein kinase Ⅱ (CaMKII).
Conclusions
AsIV could ameliorate intracellular Ca 2+ overload, apoptosis, and oxidative stress by regulating the calpain-1/CaMKII pathway, thereby improving myocardial hypertrophy and fibrosis caused by diabetes mellitus.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Second Hospital of Tianjin Medical University, Tianjin Institute of Cardiology, Tianjin, China.
- Internal Medicine-Cardiovascular Department, The First Affliated Hospital of Jinzhou Medical University, Jinzhou, China.
- Department of Biochemistry and Molecular Biology, Basic Medical College, Jinzhou Medical University, Jinzhou, Liaoning, China.
- Key Laboratory of Cardiovascular and Cerebrovascular Drug Research of Liaoning Province, Jinzhou Medical University, Jinzhou, China.
Zitieren
APA
Zhang, Q., Zhao, N., Wei, S., Lu, M., & Chen, K. (2026). Astragaloside IV prevents calpain-1-mediated cardiac hypertrophy and fibrosis induced by diabetes. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1670472
Vancouver
Zhang Q, Zhao N, Wei S, Lu M, Chen K. Astragaloside IV prevents calpain-1-mediated cardiac hypertrophy and fibrosis induced by diabetes. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1670472
BibTeX
@article{Zhang2026,
author = {Zhang, Qinglong and Zhao, Ning and Wei, Silin and Lu, Meili and Chen, Kangyin},
title = {Astragaloside IV prevents calpain-1-mediated cardiac hypertrophy and fibrosis induced by diabetes},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1670472}
}
EUVIMED